Benchmark Co. analyst Robert Wasserman maintained a Buy rating on Halozyme (HALO – Research Report) today and set a price target of $60.00. The company’s shares closed yesterday at $54.12.
Wasserman covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Halozyme, and Integer Holdings. According to TipRanks, Wasserman has an average return of 4.5% and a 38.46% success rate on recommended stocks.
Halozyme has an analyst consensus of Moderate Buy, with a price target consensus of $71.38, representing a 31.89% upside. In a report released yesterday, TD Cowen also assigned a Buy rating to the stock with a $65.00 price target.
HALO market cap is currently $6.61B and has a P/E ratio of 21.48.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Halozyme (HALO) Company Description:
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Read More on HALO:
- Halozyme price target raised to $65 from $59 at TD Cowen
- Halozyme price target raised to $64 from $59 at Morgan Stanley
- Halozyme sees FY24 non-GAAP EPS $3.65-$4.05, consensus $3.99
- Halozyme reports Q2 non-GAAP EPS 91c, consensus 78c
- HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
